LRRK2 and Parkinson disease: More importantly, our recent studies have highlighted that the continuous administration of low-dose α-MT could prevent LRRK2 mutation-induced dopaminergic neurodegeneration in transgenic Drosophila PD models and extend their lifespan [35].